Mainly, most of the psychiatric co morbidities like anxiety, depression, and psychosis are co-occurring with the cardiovascular patients in diseases like coronary artery disease, myocardial infarction, congestive heart failure, cardiomyopathy, and thus finally results in complicative and interventional treatment for the patients. The main aim of the study is to evaluate and intervene the effectiveness of the psychiatric co morbidities like anxiety, depression, and psychosis in cardiovascular patients by assessing with some of the psychiatric scales like HARS, HDRS, BPRS. In this the study illustrates the complete picture that psychiatric co morbidities like anxiety, depression, psychosis were found mainly in the age group of 50-60 in CVD patients and their prevalence is more in male patients when compared with gender wise by assessing psychiatric scales. Our findings will be useful to researchers and other clinical pharmacists, by assessing all these co morbidities in CVD patients on giving interventional management to the patients. This management finally results in improving treatment effectiveness in cardiovascular patients.